Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1749-6632.1999.tb07963.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
FAP-targeted PET/CT imaging in patients with breast cancer from a prospective bi-center study: insights into diagnosis and clinic management.
Eur J Nucl Med Mol Imaging
January 2025
Department of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Purpose: To evaluate the diagnostic accuracy and clinical impact of fibroblast activation protein (FAP)-targeted PET/CT imaging in primary and metastatic breast cancer and compare the results with those of standard-of-care imaging (SCI) and [F]FDG PET/CT.
Methods: We prospectively analyzed patients with diagnosed or suspected breast cancer who underwent concomitant FAP-targeted PET/CT (radiotracers including either [Ga]Ga-FAPI-46 or [F]FAPI-42) and [F]FDG PET/CT scans from June 2020 to January 2024 at two medical centers. Breast ultrasound (US) imaging was performed in all treatment-naïve patients as SCI.
One-day dual-tracer examination in neuroendocrine neoplasms: a real advantage of low activity LAFOV PET imaging.
Eur J Nucl Med Mol Imaging
January 2025
Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen, Otfried-Mueller-Str. 14, 72076, Tuebingen, Germany.
Purpose: Somatostatin receptor (SSTR)-PET is crucial for effective treatment stratification of neuroendocrine neoplasms (NENs). In highly proliferating or poorly differentiated NENs, dual-tracer approaches using additional [F]FDG PET can effectively identify SSTR-negative disease, usually requiring separate imaging sessions. We evaluated the feasibility of a one-day dual-tracer imaging protocol with a low activity [F]FDG PET followed by an SSTR-PET using the recently introduced [F]SiFAlin-TATE tracer in a long axial field-of-view (LAFOV) PET/CT scanner and its implications in patient management.
View Article and Find Full Text PDFCorrection to: Recent Update on PET/CT Radiotracers for Imaging Cerebral Glioma.
Nucl Med Mol Imaging
February 2025
Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine, 50‑1 Yonsei‑Ro, Seodaemun‑Gu, Seoul, 03722 Republic of Korea.
[This corrects the article DOI: 10.1007/s13139-024-00847-4.].
View Article and Find Full Text PDFCorrection to: The Development Status of PET Radiotracers for Evaluating Neuroinflammation.
Nucl Med Mol Imaging
February 2025
Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
[This corrects the article DOI: 10.1007/s13139-023-00831-4.].
View Article and Find Full Text PDFPET Reporter Probes for Brain Imaging of Transduced Gene and Cell Expression: Status and Challenges.
J Med Chem
January 2025
Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, 20892 United States.
Article Synopsis
- Gene therapy and cell transduction are emerging as promising treatments for neurological and psychiatric disorders, with PET imaging playing a key role in assessing treatment effectiveness.
- The success of PET imaging relies on the creation of specific radiotracers that can identify exogenous transgenes or modified cells in the brain, potentially eliminating the need for invasive procedures.
- This article discusses the current state and challenges in developing PET probes for monitoring gene therapy and cellular interventions, highlighting the importance of radiochemical development and practical applications in a clinical setting.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!